Volume 76, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Thirty-five individuals from endemic areas of Central Brazil (age range, 18–64 years; 19 women) in the chronic phase of Chagas disease, with positive serology and presence of circulating parasites detected by one or more recent positive xenodiagnosis, were selected for this study. Allopurinol (900 mg/d) or placebo was administered in a double-blind clinical trial for 60 days. After codes were broken, 23 had been allocated to the intervention group and 12 to the placebo group. Side effects were observed in 11 patients in the intervention group and in 1 in the placebo group. Seventeen patients in the intervention group and 10 in the placebo group completed the trial. Follow-up was performed by monthly xenodiagnosis and serologic tests every 3 months during the first year and at the end of the trial. Xenodi-agnosis remained positive in all 17 of the treated group and in all 10 of the placebo group. Serologic tests were persistently positive in both groups after treatment. We concluded that, at the doses used, allopurinol was not effective to clear, in our region, from peripheral blood of infected individuals.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Rassi A, Luquetti AO, 1992. Therapy of Chagas disease. Wendel S, Brener Z, Camargo ME, Rassi A. eds. Chagas Disease (American Trypanosomiais): Its Impact on Transfusion and Clinical Medicine. São Paulo: ISBT, 237–247.
  2. Avila JL, Avila A, Munõz E, 1981. Effect of allopurinol on different strains of Trypanosoma cruzi. Am J Trop Med Hyg 30 : 769–774. [Google Scholar]
  3. Berens RL, Maar JJ, Cruz FS, Nelson DJ, 1982. Effect of allo-purinol on Trypanosoma cruzi: metabolism and biological activity in intracellular and bloodstream forms. Antimicrob Agents Chemother 22 : 657–661. [Google Scholar]
  4. Meirovich CI, Montrull HL, Gallerano RH, Sosa RR, 1985. Alopurinol en el tratamiento de la enfermedad de Chagas cronica. Arq Bras Cardiol 45 : 217–223. [Google Scholar]
  5. Gallerano RH, Marr JJ, Sosa RR, 1990. Therapeutic efficacy of Allopurinol in patients with chronic Chagas’ disease. Am J Trop Med Hyg 43 : 159–166. [Google Scholar]
  6. Cerisola JA, Chaben MF, Lazzari JO, 1962. Test de hemagluti-nación para el diagnóstico de la enfermedad de Chagas. Prensa Med Argent 49 : 1761–1767. [Google Scholar]
  7. Camargo ME, 1966. Fluorescent antibody test for the serodiag-nosis of Chagas’ disease. Technical modification employing preserved cultural forms of Trypanosoma cruzi in a slide test. Rev Inst Med Trop Sao Paulo 8 : 227–234. [Google Scholar]
  8. Voller A, Draper C, Bidwell DE, Bartlett A, 1975. Microplate enzyme-linked immunosorbent assay for Chagas’ disease. Lancet 1 : 426–428. [Google Scholar]
  9. Luquetti AO, Rassi A, 2000. Diagnóstico laboratorial da infecção pelo Trypanosoma cruzi. Brener Z, Andrade Z, Barral-Netto M, eds. Trypanosoma cruzi e Doença de Chagas. Second edition. Rio de Janeiro: Guanabara-Koogan, 344–378.
  10. Gianella A, Holzman A, Iihoshi N, Barja Z, Peredo C, 1994. 97. Eficácia del allopurinol en la enfermedad de Chagas crónica. Resultados del estudio realizado en Santa Cruz, Bolívia. Bol Cientif CENETROP 16 : 25–30. [Google Scholar]
  11. Lauria-Pires L, Castro CN, Emanuel E, Prata A, 1988. Ineficácia do allopurinol em pacientes na fase aguda da doença de Cha-gas. Rev Soc Bras Med Trop 21 : 79. [Google Scholar]
  12. Apt W, Aguilera X, Arribada A, Pérez C, Miranda C, Sánchez G, Zulantay I, Cortés P, Rodrigues J, Juri D, 1998. Treatment of chronic Chagas’ disease with itraconazole and allopurinol. Am J Trop Med Hyg 59 : 133–138. [Google Scholar]
  13. Andrade SG, Figueira RM, 1977. Estudo experimental sobre a ação terapêutica da droga Ro 7-1051 na infecção por diferentes cepas do Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 19 : 335–341. [Google Scholar]
  14. Andrade SG, Magalhães JB, Pontes AL, 1985. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull World Health Organ 63 : 721–726. [Google Scholar]
  15. Filardi LS, Brener Z, 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Cha-gas’ disease. Trans R Soc Trop Med Hyg 81 : 755–759. [Google Scholar]
  16. Silva NN, Kuhn G, Santos JFC, Von Eye G, Chaher JAB, 1974. Eficácia e tolerância do nitrofurfurilidene na fase crônica da moléstia de Chagas. Rev Soc Bras Med Trop 8 : 325–334. [Google Scholar]
  17. Galvão LMC, Chiari E, Macedo AM, Luquetti AO, Silva AS, Andrade ALSS, 2003. PCR Assay for monitoring Trypano-soma cruzi in childhood after specific chemotherapy. J Clin Microbiol 41 : 5066–5070. [Google Scholar]
  18. Rassi A, Luquetti AO, 2004. Current chemotherapy of American trypanosomiasis. Maudlin I, Holmes PH, Miles MA, eds. The Trypanosomiases. Oxfordshire, UK: CABI, 421–429.
  19. Urbina JA, 2003. Rational approaches to specific chemotherapy of Chagas disease. Tyler KM, Miles MA, eds. American Try-panosomiases. London: Kluwer Academic, 127–135.

Data & Media loading...

  • Received : 11 Mar 2006
  • Accepted : 31 Aug 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error